AnaptysBio (ANAB) versus The Competition Financial Comparison

AnaptysBio (NASDAQ:ANAB) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare AnaptysBio to related businesses based on the strength of its analyst recommendations, valuation, dividends, institutional ownership, earnings, risk and profitability.

Profitability

This table compares AnaptysBio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AnaptysBio	82.37%	112.00%	2.20%
AnaptysBio Competitors	-12,285.98%	-196.04%	-30.61%

Earnings & Valuation

This table compares AnaptysBio and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AnaptysBio	$232.39 million	-$13.23 million	9.01
AnaptysBio Competitors	$729.47 million	$11.46 million	-14.85

AnaptysBio’s peers have higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations for AnaptysBio and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1	3	12	0	2.69
AnaptysBio Competitors	9905	15274	45607	1595	2.54

AnaptysBio presently has a consensus price target of $75.67, suggesting a potential upside of 56.40%. As a group, “Biotechnology” companies have a potential upside of 99.57%. Given AnaptysBio’s peers higher possible upside, analysts plainly believe AnaptysBio has less favorable growth aspects than its peers.

Risk and Volatility

AnaptysBio has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, AnaptysBio’s peers have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Insider and Institutional Ownership

47.7% of shares of all “Biotechnology” companies are held by institutional investors. 31.5% of AnaptysBio shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

AnaptysBio beats its peers on 7 of the 13 factors compared.

AnaptysBio Company Profile

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.